TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04187690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jin-shui Huan-xian granule
Description: Jin-shui Huan-xian granule will be administered 5days on and 2 days off for 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Jin-shui Huan-xian granule placebo
Description: Jin-shui Huan-xian granule placebo will also be administered 5days on and 2 days off for 52 weeks. The placebo consists 5% of the same components as Jin-shui Huan-xian granule besides dextrin and bitter. The There is no obvious difference in appearance, weight and odor between Jin-shui Huan-xian granule and placebo.
Study: NCT01141868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Intervention
Description: online treatment for insomnia

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Intervention
Description: online treatment for insomnia
Study: NCT03796975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Pioglitazone and Metformin Tablets
Description: 15mg/500mg, oral, 2/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride Tablets
Description: Oral metformin 850mg, 2/day in the control group
Study: NCT01818648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
Study: NCT01502072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Modified schedule of 60 milligrams/milliliter for 3-hour period 3 times/day for at least 5 days by aerosolization via a SPAG-2 generator via a face mask.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: One time loading dose of 10 mg/kg oral dose then 20 mg/kg orally (rounded to the nearest 200 mg dose) divided into three doses per day (max 1800 mg/day).
Study: NCT04086134

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruit Products
Description: Fruit Products with the potential to improve constipation-related outcomes
Study: NCT05134298

Intervention type: DRUG
Intervention: Piperacillin/tazobactam, Meropenem
Description: This is an observational study exploring the antibiotic plasma concentration profiles in ICU paitents after the first drug administration.
Study: NCT02767570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait Training; Altered Foot Progression Angle
Description: Participants will receive personalized gait training while walking on a treadmill with real-time, haptic feedback to encourage them to adopt a new foot progression angle. Participants will walk for an additional ten minutes per day to internalize their new foot progression angle over 52 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait Training; Consistent Foot Progression Angle
Description: Participants will receive personalized gait training while walking on a treadmill with haptic feedback to encourage them to maintain a consistent foot progression angle. Participants will walk an additional ten minutes per day to internalize the consistency of their foot progression angle over 52 weeks.
Study: NCT03804372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide
Description: Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
Study: NCT00984815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HZT-501
Description: Fixed-dose combination oral tablet 800mg Ibuprofen/26.6 mg Famotidine taken three times per day
Study: NCT03721068

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iC9.GD2.CAR.IL-15 T-cells
Description: Three dose levels are being evaluated: 0.5 x 10\^6, 1.0 x 10\^6, 1.5 x 10\^6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m\^2 IV dose on days 1-2 for lymphodepletion prior to cell infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 IV dose on days 1-4 for lymphodepletion prior to cell infusion
Study: NCT00590070

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adenosine
Description: Adenosine (80 mcg as fast bolus followed by 2 mg given in 33cc of saline in 2 minutes as slow bolus)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitroprusside
Description: Nitroprusside (60 mcg as fast bolus followed by 100 mcg given in 33cc of 5% glucose in 2 minutes as slow bolus)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 33 cc of heparinized saline given in 2 minutes as slow bolus
Study: NCT03403933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Didrogyl
Description: Calcifediol will be administered at a dose of 10 drops per day (as indicated for use) for 6 months or until vitamin D levels\> 30 ng / ml are obtained.~Once these values have been obtained, the dosage can be reduced to a dosage of 4/5 drops of calcifediol (1 drop contains 5mcg of calcifediol) with the aim to maintain the plasma values of 25 (OH) D in a optimal range between 30-60 ng / ml during the 6 month of the duration of the study.
Study: NCT02775747

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platelet rich plasma gel
Description: Platelet rich plasma is prepared from fresh whole blood which is collected from a peripheral vein stored in acid citrare dextrose solution A (ACD-A)anticoagulant and processed to increase platelets by separating various components of blood

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: 64 controlled women with recurrent cesarean section and fullfit to all inclusion and exclusion craiteria will reseve saline injection at time of wound closure
Study: NCT04068727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Pharmacist Intervention
Description: After randomization, the pharmacist calls patients to assess drug choice and dose. Staff distribute manufacturer coupons and help patients apply for medication payment assistance. Pharmacist discusses DOAC alternatives with prescribe and provides DOAC education by discussing potential adverse effects, medication interactions, alarm symptoms, and lab work. Staff mail educational materials. Pharmacist documents concerns in the electronic health record and messages prescriber about missing lab work. Patients share medication-related concerns. Patients are provided with a phone number for non-education calls to discuss their medications from 6 AM - 10 PM on any day. The pharmacist offers dose de-escalation instructions based on the DOAC prescription. The pharmacist advises the continuity provider on DOAC duration and monitoring. For follow-up/perioperative support, the pharmacist reviews and recommends lab monitoring and gives DOAC interruption/resumption recommendations.
Study: NCT00548691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Care (SMC)
Study: NCT01965483

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: once-weekly breast irradiation
Study: NCT03241160

Intervention type: OTHER
Intervention: Chewing evaluation
Description: Chewing evaluation will be performed. An experienced physical therapist who will take a scale training session will do the chewing evaluation according to the chewing performance scale.This scale classifies chewing function on an ordinal scale with five levels between 0 and 4 based on the sequence of functional movements during chewing.
Study: NCT00782379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: 110 mg/m2 infused over 3 hours once daily on 4 consecutive days (Days -7, -6, -5, -4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 14.5 mg/kg infused over 1-2 hours once daily on 2 consecutive days (days -3,-2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 30mg/m2 infused over 30 minutes once daily on three consecutive days (days -5, -4, -3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: 15 mg/kg po three times a daily with a maximum dose of 3gm/day starting D+5. To be discontinued on Day +35 in the absence of clinically significant GVHD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: 0.03 mg/kg/day infuse over 24 hours starting on day +5 (adjusted to maintain trough level of 5-15 ng/ml). Switch to oral (twice daily divided dose) on day +21 or when able to tolerate PO. Discontinue on day +180 in the absence of clinically significant GVHD.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Patients to received unmanipulated PBSCs on Day 0

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: patients to receive unmanipulated PBSCs on day 0
Study: NCT04481516

Intervention type: OTHER
Intervention: Yoga
Description: SKY Yoga
Study: NCT04218760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide Mononitrate 60 MG Extended Release Oral Tablet [Imdur]
Description: 1 tablet Isosorbide Mononitrate 60 mg administrated orally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: 3 blood samples from a periferal vein, two for RNA and one for metabolomics are taken right before administration of isosorbide mononitrate, 3 hours after administration of isosorbide mononitrate and again 5 hours after administration of isosorbide mononitrate.
Study: NCT00258713

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: voclosporin
Description: voclosporin 0.2, 0.3, or 0.4 mg/kg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: voclosporin
Description: voclosporin 0.2, 0.3, or 0.4 mg/kg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: voclosporin
Description: voclosporin 0.2, 0.3, or 0.4 mg/kg BID
Study: NCT02854306

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: With mindfulness programm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: With mindfulness programm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: Without mindfulness programm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: Without mindfulness programm
Study: NCT01686594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 8-methoxypsoralen
Description: 8-methoxypsoralen 10mg per 20 kg body weight 1 hour before UVA exposure
Study: NCT00911963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VCH-222 or matching placebo
Description: capsule, oral, 4 doses once daily or twice daily, 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VCH-222 or matching placebo
Description: capsule, oral, 400 mg twice daily or 750 mg twice daily, 12 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Description: subcutaneous injection, 180 μg, once weekly, 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablet, oral, 1000-1200 mg daily based on body weight, 48 weeks
Study: NCT02187822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI 287
Description: TPI 287 is an infusion given through veins. Dose escalation will begin at 14 mg/m\^2/dose. Dose expansion will begin at the maximum tolerated dose (MTD).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fractionated Stereotactic Radiotherapy (FSRT)
Description: The prescription dose will be 25 gray (Gy) in 5 daily fractions delivered to the planning target volume (PTV).
Study: NCT03420235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home monitoring program
Description: The home monitoring program consists of 1) the use of an interactive internet tool to coach patients and enhance self-management 2) home-based pulmonary function testing with a handheld spirometer and 3) recording of patient-reported outcomes (PROs).
Study: NCT00802841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Description: Supplied as 200 mg tablets
Study: NCT03616093

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Beet Shot
Description: Active supplement containing 6.2 mmol nitrate
Study: NCT00802841

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imatinib
Description: Supplied as 100 mg and 400 mg tablets
Study: NCT03342911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT03279705

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Water jet channel
Description: The separate water jet channel was used for infusing water.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accessory channel
Description: The accessory channel was used for infusing and/or suctioning water

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accessory channel
Description: The accessory channel was used for infusing and/or suctioning water
Study: NCT03616093

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Beverage
Description: Placebo supplement containing negligible nitrate
Study: NCT04351490

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc gluconate
Description: Zinc gluconate capsule 15 mg x 2 per day during 2 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 25-OH cholecalciferol
Description: 25-OH cholecalciferol drinkable solution 10 drops (2000 IU) per day during 2 months
Study: NCT00377741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valganciclovir [Valcyte]
Description: 900mg po
Study: NCT00862875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Detemir or Glargine
Description: Initial dose of 10 units of insulin at bedtime. The insulin dose will be increase by 1 unit per day until fasting plasma glucose (FPG) levels are 5.0 mmol/L.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Detemir or Glargine
Description: Initial dose of 10 units of insulin at bedtime. The insulin dose will be increase by 1 unit per day until fasting plasma glucose (FPG) levels are 5.0 mmol/L.
Study: NCT01973465

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stool
Description: Implanting fecal matter via colonscope
Study: NCT02176928

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AutoPAP
Description: PAP will be delivered by an auto-titrating device (IntelliPAP AutoAdjust®). These devices automatically set the level of delivered pressure to ensure upper airway patency, to treat detected apneas and hypopneas.~AutoPAP treatment 7 nights a week for four months (16 weeks).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham PAP
Description: Sham PAP treatment will be delivered by an auto-PAP device (IntelliPAP AutoAdjust®) that is set to a fixed low pressure of 3 cmH20 without an ability to titrate according to detected respiratory events. The pressure is too low to eliminate respiratory events and serves as sham or sub-therapeutic PAP.~Sham PAP treatment 7 nights a week for four months (16 weeks)./
Study: NCT00360555

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: flibanserin
Description: flibanserin 25 mg b.i.d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flibanserin 50mg
Description: flibanserin 50mg qhs/b.i.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flibanserin 100mg
Description: flibanserin 50 mg b.i.d/100mg qhs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo comparator
Study: NCT01917734

Intervention type: OTHER
Intervention: Therapeutic feeding for children with SAM
Description: Comparison of outcomes between children with complicated SAM and children with uncomplicated SAM as well as comparisn of outcomes against national and internationally agreed upon standards of care
Study: NCT00163215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: Adapted dosage based on IGF 1 level and weight Form: liquid; Dosage and Frequency: from 0.0033mg/kg/day to 0.0067 mg/kg/day; Duration: 3 years
Study: NCT00739583

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHG 2% w/v and IPA 70% v/v
Description: Skin preparation of the surgical site per label of the product. The area for surgery will be prepared for 30 seconds

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodophor 0.7% and IPA 74% w/w
Description: Skin preparation of the surgical site per product labeling. The area will be painted with the solution.
Study: NCT03567083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Management Plus (PM+)
Description: This intervention is based on the WHO treatment guidelines for conditions related to stress (WHO, 2013). It is a 5-session intervention that is delivered by trained non-specialized workers or lay people, and is available in individual and group delivery formats for both children and adults. PM+ includes evidence-based techniques such as; problem solving, stress management, behavioral activation, and accessing social support. It has proved to be effective by two randomized controlled trials (RCTs) in Kenya and Pakistan (Bryant, Dawson, Schafer, Sijbrandij, \& van Ommeren, 2016; Rahman, Hamdani, Awan, Bryant, Dawson, Khan, Mukhtar-ul-Haq Azeemi, et al., 2016).
Study: NCT02079207

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP606
Description: 13-valent peumococcal conjugate vaccine(13vPnC)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prodiax-23
Description: 23-valent peumococcal polysaccharide vaccine(23vPS)
Study: NCT02372175

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)
Description: Dengue subtype 1 Challenge Virus (DENV-1) strain 45AZ5 administered as a single injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)
Description: Dengue subtype 1 Challenge Virus (DENV-1) strain 45AZ5 administered as a single injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)
Description: Dengue subtype 1 Challenge Virus (DENV-1) strain 45AZ5 administered as a single injection.
Study: NCT00401466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Cardioverter Defibrillator
Description: ICD with Biotronik Home Monitoring capability

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Cardioverter Defibrillator
Description: ICD with Biotronik Home Monitoring capability
Study: NCT03135132

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Recommend to consume usual diet during 12-week study period

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LCD group
Description: Recommended to reduce calorie intake (a 300 kcal/day); educated to take out 1/3 of a bowl of rice from per meal a day for an easier application of 100kcal deficits, thereby reducing a 300kcal/3 meal/day
Study: NCT01084928

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention Classes
Description: The intervention will be based on the Diabetes Prevention Program but tailored to the needs of the community based on feedback gathered in focus groups. Classes will be group-based and will use a variety of teaching techniques and group-based work to teach participants about behavior change, diet, and physical activity. Participant will be required to attend one group exercise class per week based on traditional Indian dances and other culturally appropriate activities. In order to reach their weekly exercise goal of 150 minutes or more per week, participants will also be able to attend an additional group exercise class, an organized group walk, do a culturally-tailored work out video created by the study staff, and/or exercise on their own.
Study: NCT00506285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Transdermal System (MTS)
Description: MTS is an advanced patch product that provides methylphenidate evenly mixed with the adhesive. This formulation allows good adhesion and a wide range of dose sizes. MTS patch sizes of 12.5, 18.75, 25 and 37.5cm2 are equivalent to nominal doses over a 9-hour wear time of 10, 15, 20 and 30mg of MPH.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo patch
Description: This patch is designed to appear identical to the actual intervention patch
Study: NCT05054829

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PEERS®: program for the education and enrichment of relational skills
Description: providing evidence-based social skills treatment to preschoolers, adolescents, and young adults with autism spectrum disorder (ASD)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEERS®: program for the education and enrichment of relational skills
Description: providing evidence-based social skills treatment to preschoolers, adolescents, and young adults with autism spectrum disorder (ASD)